MedPath

Nemtabrutinib Shows Promise in Relapsed/Refractory Follicular Lymphoma

• Nemtabrutinib demonstrates encouraging efficacy in patients with relapsed or refractory follicular lymphoma, according to findings from the BELLWAVE-003 phase 2 trial. • The study, presented at the 2024 ASH Annual Meeting, highlights the potential of nemtabrutinib as a treatment option for this patient population. • Safety data from the trial indicate a manageable toxicity profile, supporting the continued investigation of nemtabrutinib in follicular lymphoma. • Further research is warranted to confirm these findings and explore the optimal use of nemtabrutinib in the treatment landscape.

Nemtabrutinib is emerging as a potential therapeutic option for patients with relapsed or refractory follicular lymphoma. Data from the phase 2 BELLWAVE-003 study (NCT04728893), presented at the 2024 ASH Annual Meeting, showcase the efficacy and safety profile of this agent in a challenging patient population.

BELLWAVE-003 Study Details

The BELLWAVE-003 trial is a phase 2 study evaluating the efficacy and safety of nemtabrutinib in patients with relapsed or refractory follicular lymphoma. Key findings from the study were presented by Wojciech Jurczak, MD, PhD, from the Maria Sklodowska-Curie National Research Institute of Oncology.

Efficacy and Safety

The results indicate that nemtabrutinib demonstrates promising activity in this setting, with a manageable safety profile. Further details regarding specific response rates and adverse events are anticipated to be released in forthcoming publications. "Nemtabrutinib shows encouraging efficacy in patients with relapsed or refractory follicular lymphoma," stated Dr. Jurczak.

Follicular Lymphoma Context

Follicular lymphoma is an indolent form of non-Hodgkin lymphoma characterized by slow growth and relapse patterns. While various treatment options exist, including chemotherapy, immunotherapy, and targeted therapies, a significant proportion of patients experience relapse or become refractory to these treatments. Therefore, novel agents with distinct mechanisms of action are needed to address this unmet medical need. Nemtabrutinib represents a potential advancement in the treatment paradigm for relapsed/refractory follicular lymphoma.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Highlighted Clinical Trials

Related Topics

Acalabrutinib Regimen Shows Promise in Untreated Mantle Cell Lymphoma

Acalabrutinib, umbralisib, and ublituximab (AU2) demonstrated a 100% objective response rate in patients with de novo mantle cell lymphoma (MCL).
The regimen achieved high rates of undetectable minimal residual disease (uMRD), suggesting deep remission in responding patients.

Monjuvi Combination Shows Promise in Relapsed/Refractory Follicular Lymphoma

The combination of Monjuvi, Revlimid, and Rituxan significantly reduces the risk of disease progression or death in relapsed/refractory follicular lymphoma patients.
The inMIND phase 3 trial demonstrated a median progression-free survival of 22.4 months with the Monjuvi combination, compared to 13.9 months with Revlimid and Rituxan alone.

Merck Highlights Hematology Pipeline at ASH 2024 with Zilovertamab Vedotin and Nemtabrutinib Data

Merck is presenting data at ASH 2024 showcasing its hematology pipeline, including investigational assets like zilovertamab vedotin and nemtabrutinib.
Phase 2 results for zilovertamab vedotin combined with chemotherapy in newly diagnosed diffuse large B-cell lymphoma (DLBCL) will be presented.

Phase 3b Study Shows Promise for Moderate Psoriasis in Sensitive Areas

A Phase 3b study presented at Fall Clinical 2024 indicates potential efficacy in clearing moderate psoriasis in sensitive areas for patients who have not responded to topical treatments.
The conference also featured discussions on advanced dermatology treatments, emphasizing clinical trial inclusivity and key care strategies for complex skin conditions.

Epcoritamab Approved by FDA for Relapsed/Refractory Follicular Lymphoma

The FDA has granted accelerated approval to epcoritamab for relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
The approval was based on the phase 1/2 EPCORE NHL-1 trial, which demonstrated an 82% overall response rate and a 60% complete response rate.

Emavusertib-Based Therapy Shows Promise in BTK Inhibitor-Refractory PCNSL

Emavusertib, an IRAK4 and FLT3 inhibitor, has shown potential in overcoming resistance to BTK inhibitors in primary central nervous system lymphoma (PCNSL).
The TakeAim Lymphoma trial is evaluating emavusertib in combination with ibrutinib for relapsed/refractory PCNSL, demonstrating encouraging early responses in BTK inhibitor-refractory patients.

Belzutifan Shows Sustained Efficacy in VHL-Associated CNS Hemangioblastomas

Belzutifan demonstrates meaningful antitumor activity in von Hippel-Lindau (VHL) disease-associated central nervous system (CNS) hemangioblastomas, with efficacy sustained over three years.
In a Phase II trial, 44% of patients with VHL-associated CNS hemangioblastomas achieved an objective response with belzutifan, and 46% experienced stable disease.

Tafasitamab Regimen Shows Promise in Improving PFS for Advanced Follicular Lymphoma Patients

A recent phase 3 trial demonstrates that adding tafasitamab-cxix to lenalidomide and rituximab significantly improves progression-free survival (PFS) in patients with relapsed or refractory follicular lymphoma, with no new safety concerns reported.

Odronextamab Demonstrates High Efficacy in Lymphoma Treatments at ASH Meeting

New data presented at the 66th ASH Annual Meeting highlights odronextamab's potential in treating various B-cell non-Hodgkin lymphoma subtypes, showing complete responses in untreated follicular lymphoma and durable responses in diffuse large B-cell lymphoma post CAR-T therapy.

Phase 2 Trial Shows High Efficacy of BOVen Regimen in Treating Chronic Lymphocytic Leukaemia

A phase 2 trial investigating the BOVen regimen (zanubrutinib, obinutuzumab, and venetoclax) for treating chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) has shown promising results, with 89% of patients achieving undetectable minimal residual disease (MRD) in both peripheral blood and bone marrow. The study highlights the regimen's safety and efficacy, suggesting a potential new standard for first-line therapy in CLL/SLL patients.

Reference News

[1]
Dr Jurczak on the Efficacy and Safety of Nemtabrutinib in R/R Follicular Lymphoma
onclive.com · Dec 7, 2024

Wojciech Jurczak, MD, PhD, from the Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy